Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia

Immunotherapy
Marvin M van LuijnArjan A van de Loosdrecht

Abstract

During onset, treatment and progression of acute myeloid leukemia (AML), inadequate immune responses against certain myeloid leukemic blasts might be associated with the occurrence of minimal residual disease and subsequent relapse. Several studies on this subject have demonstrated that, in general, solid tumor cells are able to avoid CD8(+) cytotoxic T-cell recognition by downregulating HLA class I-restricted presentation of tumor-associated antigens. In tumor cells that can express HLA class II molecules, such as myeloid leukemic blasts, abnormalities in the processing pathways of endogenous antigens could also result in impaired HLA class II-restricted tumor-associated antigen presentation to CD4(+) T helper cells. More insight into impaired tumor-associated antigen presentation by myeloid leukemic blasts could explain their escape from immune recognition and might be crucial for selecting appropriate strategies to improve whole-cell or dendritic cell-based tumor vaccine efficacy in the treatment of AML patients.

References

Mar 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·M S Anderson, J Miller
Jan 1, 1991·International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement·O BlanchetP Paul
Jan 3, 1995·The EMBO Journal·P BénarochH L Ploegh
Jun 29, 1995·Nature·V S SloanD M Zaller
Jan 1, 1995·Annual Review of Cell and Developmental Biology·P R Wolf, H L Ploegh
Jun 1, 1997·Immunology Today·B SeligerS Ferrone
Jun 24, 1997·Proceedings of the National Academy of Sciences of the United States of America·T D ArmstrongS Ostrand-Rosenberg
Jul 1, 1997·Immunology·A K SimonA M Schmitt-Verhulst
Jan 13, 2000·Immunological Reviews·P CresswellG Diedrich
Mar 29, 2001·Nature Immunology·M J SmythJ A Trapani
Oct 23, 2001·International Journal of Cancer. Journal International Du Cancer·A SerranoF Garrido
Dec 12, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·C RoucardM van Ham
Jan 22, 2002·International Journal of Cancer. Journal International Du Cancer·Nienke van der StoepPeter J van den Elsen
Oct 24, 2002·Current Opinion in Hematology·J H F FalkenburgR Willemze
Oct 31, 2002·Nature Immunology·Gavin P DunnRobert D Schreiber
Feb 13, 2003·British Journal of Haematology·Alastair WhitewayH Grant Prentice
Apr 12, 2003·Leukemia·M WetzlerM R Baer
Apr 22, 2003·Journal of Cellular Physiology·Angel Garcia-LoraFederico Garrido
May 6, 2003·European Journal of Immunology·Falk NimmerjahnJosef Mautner
Dec 14, 2004·Science·Casper PaludanChristian Münz
May 14, 2005·Cancer Immunology, Immunotherapy : CII·Adam T C CheukBarbara-ann Guinn
May 17, 2005·Immunity·Delu ZhouJanice S Blum
May 17, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jörn DengjelStefan Stevanovic
Jul 13, 2005·Cancer Immunology, Immunotherapy : CII·K L Knutson, M L Disis
Sep 1, 2005·Immunogenetics·Durjoy MajumderSubrata Banerjee

❮ Previous
Next ❯

Citations

Dec 22, 2012·Immunotherapy·Felix S LichteneggerMarion Subklewe
Jul 23, 2013·Blood Reviews·Anna MartnerKristoffer Hellstrand
Jun 2, 2016·Critical Reviews in Oncology/hematology·Rebecca AustinSteven W Lane
Jul 12, 2016·Nature Communications·Joshy GeorgeJennifer J Trowbridge
Jun 19, 2016·Blood·Miguel M Leiva-JuárezScott E Evans
Feb 19, 2019·HLA : Immune Response Genetics·Sholhui ParkJungwon Huh
Jul 25, 2019·HLA : Immune Response Genetics·Antonio BalasJosé L Vicario
Aug 5, 2015·Pharmacological Reviews·Sébastien AnguilleZwi N Berneman
Jan 13, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sophia KhaldoyanidiMarion Subklewe

❮ Previous
Next ❯

Methods Mentioned

BETA
CLIP
transfection

Related Concepts

Related Feeds

Auditory Perception

Auditory perception is the ability to receive and interpret information attained by the ears. Here is the latest research on factors and underlying mechanisms that influence auditory perception.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.